We are joined by Professor Michael Böhm. He is the director of the Clinic for Internal Medicine III and Chief of Cardiology at the University of the Saarland in Germany.

He has a special interest in pathophysiology and treatment of heart failure and has been the principal investigator of several multicentre clinical trials. He has written more than 700 original papers, book chapters and review articles and is a past president of the German Society of Cardiology.

For this episode, we will explore some real-world examples of the use of empagliflozin.

“This series of medical educational podcasts and associated materials have been sponsored by Boehringer Ingelheim and Lilly Alliance (The Alliance). The Alliance had no influence over the agenda, programme development, content or selection of the faculty. Editorial and content decisions were made solely by Oruen Limited, and faculty chosen by Oruen Limited”

“Not intended for US & UK based healthcare professionals”.

Episode 5 - The use of SGLT2 inhibitors in patients hospitalised for acute heart failure - Prof. Christiane Angermann

We are joined by Professor Christiane Angermann. Prof Angermann is a Senior Professor of Medicine and Clinical Research in Cardiology at the University and University Hospital Würzburg in Germany, and co-founder of the Comprehensive Heart Failure Centre Würzburg (CHFC). She acted as coordinating investigator in the Executive Committee of the EMPULSE trial, a multinational clinical trial evaluating the clinical benefit of empagliflozin in patients who were stabilised after hospitalisation for acute heart failure. She has published over 240 peer-reviewed articles and is currently editor-in-chief for Current Heart Failure Reports.

For this episode, we will explore the potential for the use of empagliflozin in patients who are hospitalised with heart failure.

References:

Voors, AA, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat. Med., 2022; 28,: 568–574. https://doi.org/10.1038/s41591-021-01659-1

Biegus, J, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial, European Heart Journal, 2022; ehac530, https://doi.org/10.1093/eurheartj/ehac530

Mebazaa, A, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.

Lancet. 2022; 400: 1938–1952. https://doi.org/10.1016/S0140-6736(22)02076-1 

Voors, AA, et al. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation 2022; 146: 279–288. https://doi.org/10.1161/CIRCULATIONAHA.122.059725

Emmens, JE, et al. Worsening renal function in acute heart failure in the context of diuretic response. Eur J Heart Fail. 2022;  24: 365-374. https://doi.org/10.1002/ejhf.2384

“This series of medical educational podcasts and associated materials have been sponsored by Boehringer Ingelheim and Lilly Alliance (The Alliance). The Alliance had no influence over the agenda, programme development, content or selection of the faculty. Editorial and content decisions were made solely by Oruen Limited, and faculty chosen by Oruen Limited”. 

“Not intended for US & UK based healthcare professionals”.

Episode 4 - Treatment options in patients with heart failure across the spectrum of left ventricular ejection fraction with a particular interest in the pooling of previous results to gain greater insight. - Dr. Milton Packer

We are joined by Dr. Milton Packer. He is a Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center, Dallas in the United States. He is also a visiting professor at Imperial College London. He is one of the world leaders in the field of heart failure, has been a member of the FDA for over 30 years and founded the Heart Failure society of the America, He has published over 500 peer-reviewed articles, reviews, and editorials along with over 30 book chapters in the field.

For this episode, we will look at what further insights can be gained from pooling these results and hear the potential of empagliflozin as a treatment approach for patients right across the ejection fraction spectrum.

References:

Butler J, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022;43(5):416-426. doi:10.1093/eurheartj/ehab798

Packer, M, et al. Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. Eur J Heart Fail, 22: 2393-2398. doi: 10.1002/ejhf.2065

Butler J, et al. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation. 2022;145(3):184-193. doi:10.1161/CIRCULATIONAHA.121.057812

Butler J., et al. Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR-Preserved Trial. Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2420

Ferreira JP, et al. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled, Eur Heart J. 2022;43(31):2984-2993. doi:10.1093/eurheartj/ehac306  (there is a correction on this in relation to author affiliations, not the results).

“This series of medical educational podcasts and associated materials have been sponsored by Boehringer Ingelheim and Lilly Alliance (The Alliance). The Alliance had no influence over the agenda, programme development, content or selection of the faculty. Editorial and content decisions were made solely by Oruen Limited, and faculty chosen by Oruen Limited”. 

“Not intended for US & UK based healthcare professionals”.